AcuCort receives marketing authorization for the drug Zeqmelit by the Norwegian Medicines Agency
AcuCort AB (publ) (Spotlight Stock Market: ACUC) today announces that the Norwegian Medicines Agency, Statens legemiddelsverk, has approved the company’s first drug under the name Zeqmelit in Norway.In the development of the drug Zeqmelit/ISICORT[®], AcuCort has managed to combine the benefits of the well-proven substance dexamethasone and the patented user-friendly oral film for quick availability and relief in emergency situations such as severe and acute allergic reactions. The drug was recently approved in Denmark under the name Zeqmelit and has previously been approved in Sweden